Who we are

TOPADUR Pharma AG is a Swiss biopharmaceutical start-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. We strive for significant improvement of patients’ quality of life while providing sustainable high growth value for investors and employees.

About us

WHAT WE DO

The company has discovered and developed DualTOP™ technology platform consisting of new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. The DualTOP™ technology will promote healthy long life.

Pipeline

WHAT WE SOLVE

Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases. They stimulate capillary blood flow with unprecedented potency and efficacy, and address the problems caused by endothelial dysfunction.

Our Approach

latest news

Press Release
November 10, 2020

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

Read More

TOPADUR Pharma AG: From Idea to Solution

We are enhancing quality of life through ground-breaking research.

About us

Our dual-mode of action drugs target the cGMP-Enzyme Regulation System.

Our Approach

Discover our pipeline where we provide you with an overview of all major projects at TOPADUR.

Pipeline

cGMP-Enzyme Regulation System

Problem

Aging processes are characterized by a reduction in blood circulation and dysregulation in cell-cell communication. The misbalance of cGMP levels leads to diseases like chronic wounds, skin fibrosis, glaucoma, colorectal cancer, hair loss and skin aging.

Solution

TOPADUR designed new drugs that target the cGMP-Enzyme Regulation System. TOPADUR’s compounds regulate the activity of sGC and PDE5 enzymes to increase the level of cGMP. This ultimately enables blood circulation and corrects the insufficient cell-cell communication.

News

10.11.2020
Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

Read more
27.10.2020
News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

Read more
8.10.2020
News

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.

Read more
Go to News

What drives us

Luzia
Research & Development

I greatly appreciate the collaborative nature of the projects at TOPADUR where my contribution and ideas make a difference.

Esra
Research & Development

Being part of TOPADUR from the beginning, experiencing its growth and contributing to its success has been a privilege. With exciting projects and results, TOPADUR is an attractive workplace.

Rita
Project Management

I am inspired by TOPADUR's commitment to developing new drugs that will have a meaningful impact on peoples’ lives.

Michael
Research & Development

TOPADUR’s entrepreneurial spirit enables me to combine conceptual work with practical application in the laboratory and thus create something meaningful.

Tobias
Research & Development

With a team of highly passionate people with various specialist skills and background, Topadurians develop together innovative therapeutic options with a common goal of helping patients in need.

Giancarlo
IT

Taking part in the development of TOPADUR and seeing its progress motivates me.

Awards